A variation to the clinical staging of AD was proposed by the National Institute on Aging – Alzheimer’s Association (NIA-AA) working group (2018) using six clinical stages for persons who are amyloid positive.
The NIA-AA Research Framework describes AD as a biological construct that can be identified in living persons via Aβ and tau biomarkers.
In the NIA-AA framework, biomarkers are used to identify the presence of AD, with clinical stages used to indicate disease severity.
Read more about New clinical staging of Alzheimer’s disease
Related content
Brain drug delivery systems, allied with their characteristics for overcoming the blood-brain barrier (BBB).
The use of a single treatment in heterogeneous populations has proved problematic in clinical trials undertaken in patients with neurodegenerative diseases.